Skip to content

HFpEF and 2-year Mortality of COPD Patients

The Influence of hearT Failure With Preserved Ejection Fraction on 2year Mortality of Patients With cHronic obstructivE pulmonaRy disEaSE- THERESE Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04277429
Acronym
THERESE
Enrollment
150
Registered
2020-02-20
Start date
2020-07-01
Completion date
2025-04-01
Last updated
2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Heart Failure

Brief summary

This study was designed to assess potential relationship between heart failure with preserved ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary disease

Interventions

DIAGNOSTIC_TESTCardiac function assessment

Echocardiography, cardiac enzymes analysis

Sponsors

University Hospital Olomouc
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Exacerbation of chronic obstructive pulmonary disease requiring hospitalization Age 40 - 80 years Performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG) Long acting beta agonist (LABA)/ long acting antimuscarinic (LAMA) bronchodilator treatment

Exclusion criteria

Presence of major heart valve dysfunction Documented noncompliance with treatment Presence of active malignancy Body mass index \> 40 Interstitial lung disease

Design outcomes

Primary

MeasureTime frameDescription
Mortality2 yearMortality of patients

Countries

Czechia

Contacts

Primary ContactMilan Sova, Ph.D.
milan.sova@email.cz588445326
Backup ContactOndrej Zela, MD
ondrej.zela@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026